Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs

Alessandro Roggeri BSc, Ferruccio Conte MD, Carlotta Rossi MSc, Mario Cozzolino MD, PhD, Carlo Zocchetti MSc, Daniela Paola Roggeri MSc

Article Type

Original Research

Published

This retrospective observational study evaluated, in dialysis patients with SHPT, the impact of different levels of adherence to cinacalcet therapy on hospitalisations and direct healthcare costs charged to the Lombardy Regional Health Service (Italy).

Read more

Considerations for the US health-system pharmacist in a world of biosimilars

Andrea Zlatkus CRHC, Todd Bixby RPh, Kavitha Goyal MD

Article Type

Editorial

Published

This editorial article provides an overview of the evolving healthcare landscape shaped by the entry of multiple biosimilars, including for a given reference product, and their impact on the healthsystem pharmacist with respect to formulary assessment, implementation, and education of various health-system stakeholders, including patients.

Read more

Clinical trials: their contribution to the efficiency of the clinical management of rheumatoid arthritis

Cristina P Alcañiz Escandell MD, José A Román Ivorra PhD

Article Type

Original Research

Published

This article presents a descriptive analysis of theClinical Research Unit (CRU) at the Rheumatology Department in the University and Polytechnic Hospital La Fe (RD-UPH La Fe), Valencia (Spain), as well as an estimation of the economic impact of conducting clinical trials for the Spanish Health System in terms of avoided costs.

Read more

Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII)

Neon Brooks, Mario Campone, Silvia Paddock, Scott Shortenhaus, David Grainger, Jacqueline Zummo, Samuel Thomas, Rose Li

Article Type

Original Research

Published

This article examines the relationship between U.S. Food and Drug Administration (FDA) approval and the publication of OS evidence to understand better the risks and benefits of delaying approval until OS evidence is available.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.